Ageing well: becoming a world leader in tackling dementia and Alzheimer’s

Best of the Spectator

The Spectator

Society & Culture, News Commentary, News, Daily News

4.3 • 826 Ratings

🗓️ 26 February 2024

⏱️ 46 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

With cases of neurodegenerative conditions rising in the UK, it's crucial to re-examine how we tackle these diseases. The Spectator's assistant editor Isabel Hardman speaks to Debbie Abrahams MP (co-chair of the Dementia APPG), Dr Emily Pegg (associate vice president at Eli Lilly), Dr Susan Kohlhaas (executive director at Alzheimer's Research), and Professor Giovanna Mallucci (principal investigator at the Cambridge Institute of Science).

Eli Lilly and Company has provided sponsorship funding to support this event, and has had no influence over the content of the event or selection of speakers

Hosted on Acast. See acast.com/privacy for more information.

Transcript

Click on a timestamp to play from that location

0:00.0	The Spectator magazine combines incisive political analysis with books and arts reviews of unrivaled authority.
0:07.6	Subscribe today for just £12 and receive a 12 week subscription, in print and online, plus a £20 £20,000, Amazon gift voucher, absolutely free.
0:17.3	Go to spectator.com.uk forward slash voucher.
0:26.5	I'm Mr. Val Harbin. I'm the assistant editor at The Spectator and author of a book on the history of the NHS, which comes out in paperback tomorrow, just so you know.
0:35.0	But thank you so much for coming to this panel on Aging Well,
0:38.4	making the UK a world leader in tackling dementia and Alzheimer's. We've got a fantastic
0:44.5	panel of experts on this topic to talk to you this afternoon. We're going to have a discussion
0:50.8	and then we're going to open up to questions on this. So I'm joined by
0:55.3	Susan Mitchell, who is Head of Policy at Alzheimer's Research, Emily Pegg, who is Associate
1:00.5	Vice President of Eli, of Medical, at Lilly Northern Europe. And I should say that Eli Lilly
1:06.2	are sponsoring this panel to support this event, but they have no influence over the content of the
1:11.2	event or the selection of the speakers, as discussed in the previous discussion.
1:17.4	Debbie Abrams is a Labour MP. She's also chair of the APPG for dementia, and Professor Giovanna
1:24.3	Malucci is principal investigator of Altos Labs in Cambridge, the Cambridge
1:29.2	Institute of Science. So I don't think you could get a better panel to discuss this. And so often
1:36.2	discussions about dementia can be quite downbeat, not least because of the way in which the NHS and
1:41.4	social care, do I want to say services or lack of services quite often,
1:45.5	tend to interact or not. But we've decided to make this research focus. We've decided to make this
1:50.7	about the future of dementia research and treatment in the United Kingdom and whether the
1:56.4	ambition so often articulated by politicians that this country is going to be a science superpower
2:01.6	could extend to research within the dementia sphere. So I think it would be great to start
2:08.3	with Susan to talk about the research landscape, to talk about where we are, about how hopeful,
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from The Spectator, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of The Spectator and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.